1. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.
- Author
-
Carberry J, Petrie MC, Lee MMY, Brooksbank K, Campbell RT, Good R, Jhund PS, Kellman P, Lang NN, Mangion K, Mark PB, McConnachie A, McMurray JJV, Meyer B, Orchard V, Shaukat A, Watkins S, Welsh P, Sattar N, Berry C, and Docherty KF
- Subjects
- Humans, Double-Blind Method, Male, Female, Stroke Volume physiology, Stroke Volume drug effects, Middle Aged, Aged, Disease Progression, Follow-Up Studies, Benzhydryl Compounds therapeutic use, Myocardial Infarction drug therapy, Ventricular Remodeling drug effects, Glucosides therapeutic use, Glucosides pharmacology, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Magnetic Resonance Imaging, Cine methods, Ventricular Function, Left physiology, Ventricular Function, Left drug effects
- Abstract
Aims: Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The early addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients., Methods and Results: EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS-MI) is a randomized, double-blind, placebo-controlled, multi-centre trial designed to assess the effect of empagliflozin on cardiac remodelling evaluated using cardiovascular magnetic resonance (CMR) in 100 patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by CMR. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome will be change in left ventricular end-systolic volume indexed to body surface area over 24 weeks from randomization. Secondary endpoints include measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and circulating cardiac biomarkers., Conclusions: EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI., (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF